[
  {
    "ts": null,
    "headline": "AstraZeneca: Oncology Dominance Justifies New All-Time Highs",
    "summary": "AstraZeneca hit a 2026 high on strong oncology/cardiovascular sales.",
    "url": "https://finnhub.io/api/news?id=37fedf41221f724240bb6e5a39b561db6df5999f1666745993872e232235f2b3",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1768039200,
      "headline": "AstraZeneca: Oncology Dominance Justifies New All-Time Highs",
      "id": 138056039,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1357662733/image_1357662733.jpg?io=getty-c-w1536",
      "related": "PFE",
      "source": "SeekingAlpha",
      "summary": "AstraZeneca hit a 2026 high on strong oncology/cardiovascular sales.",
      "url": "https://finnhub.io/api/news?id=37fedf41221f724240bb6e5a39b561db6df5999f1666745993872e232235f2b3"
    }
  },
  {
    "ts": null,
    "headline": "2026 is the year of obesity pills. Here's how they could reshape the GLP-1 market",
    "summary": "Patients can already access the first GLP-1 obesity pill from Novo Nordisk, and a rival oral drug from Eli Lilly is slated for U.S. approval later this year.",
    "url": "https://finnhub.io/api/news?id=0ef44fbf4b4de83c0e82bc17f6a38c818f9abb8935eb227d5b1980953b744477",
    "source": "CNBC",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1768032001,
      "headline": "2026 is the year of obesity pills. Here's how they could reshape the GLP-1 market",
      "id": 138057241,
      "image": "https://image.cnbcfm.com/api/v1/image/108231152-17640105232025-11-24t185245z_617754530_rc263iabxpyr_rtrmadp_0_novo-nordisk.jpeg?v=1764010568&w=1920&h=1080",
      "related": "PFE",
      "source": "CNBC",
      "summary": "Patients can already access the first GLP-1 obesity pill from Novo Nordisk, and a rival oral drug from Eli Lilly is slated for U.S. approval later this year. ",
      "url": "https://finnhub.io/api/news?id=0ef44fbf4b4de83c0e82bc17f6a38c818f9abb8935eb227d5b1980953b744477"
    }
  }
]